clinical trial · NCT04957719
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
Viatris Innovation GmbH·phase3·enrolling by invitation·n = 25,000
Acute Myocardial InfarctionSelatogrelPlacebo
brief summary
This study will randomize patients recently discharged from the hospital with a confirmed diagnosis of type 1 acute myocardial infarction (Thygesen et al. 2018) and having additional cardiovascular risk factors.
started
Aug 14, 2021
primary completion
Dec 1, 2026
completion
Dec 1, 2026
last updated
May 13, 2026
detailed description
The purpose of this study is to assess the clinical efficacy of selatogrel when self-administered upon occurrence of symptoms suggestive of an acute myocardial infarction (AMI) in participants at risk of having a recurrent AMI.
official title
Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Self-administered Subcutaneous Selatogrel for Prevention of All-cause Death and Treatment of Acute Myocardial Infarction in Subjects With a Recent History of Acute Myocardial Infarction
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol